Aurinia Pharmaceuticals Inc. cash flow statement
In fiscal 2025, Aurinia Pharmaceuticals Inc.'s operations generated $136m of cash. It returned $98.2m through buybacks.
Cash flow statement
| Fiscal year | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | −19 | −41 | −52 | −64 | −70 | −158 | −80 | −33 | 44 | 136 | 177 |
| Depreciation and amortisation | — | — | 0 | 0 | 1 | 3 | 3 | 12 | 19 | 19 | 19 |
| Stock-based pay | 1 | 4 | 7 | 7 | 17 | 31 | 32 | 45 | 32 | 15 | 15 |
| Capital spending | 0 | 0 | — | — | — | — | — | — | — | — | — |
| Free cash flow | −19 | −41 | — | — | — | — | — | — | — | — | — |
| Free cash flow after stock pay | −20 | −45 | — | — | — | — | — | — | — | — | — |
| Share buybacks | — | — | — | — | — | — | 0 | 0 | 40 | 98 | 75 |
| Shares issued | — | — | 0 | 223 | 188 | 197 | 2 | 2 | 1 | 1 | — |
| Quarter | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 | 2026 Q3Sept 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 30 | 1 | 44 | 44 | 46 | 33 | 53 | 46 |
| Depreciation and amortisation | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Stock-based pay | 9 | −3 | 5 | 6 | 7 | −1 | 3 | 6 |
| Shares issued | 0 | — | — | 0 | 0 | — | — | 0 |
Compare with peers
- Iovance Biotherapeutics, Inc. cash flow
- Arvinas, Inc. cash flow
- Adaptive Biotechnologies Corp cash flow
- Vericel Corp cash flow
- Vir Biotechnology, Inc. cash flow
Head to head: AUPH vs IOVAARVN vs AUPHADPT vs AUPH
More: Biotechnology stocks compared, Health Care sector, rankings of US companies